FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 251 filers reported holding FATE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $8,983,000 | -57.1% | 153,537 | -56.5% | 1.37% | -64.4% |
| Q3 2021 | $20,937,000 | -28.2% | 353,250 | +5.2% | 3.85% | -18.1% |
| Q2 2021 | $29,154,000 | -74.2% | 335,918 | -75.5% | 4.70% | -78.7% |
| Q1 2021 | $112,967,000 | +30.4% | 1,370,133 | +43.8% | 22.12% | -8.5% |
| Q4 2020 | $86,642,000 | – | 952,847 | – | 24.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |